T-cell receptor gamma delta (TCRGD)

The T-cell receptor gamma delta (TCR gamma delta) is a multi-subunit protein complex expressed on the surface of gamma delta T cells, which represent a unique lineage of T lymphocytes bridging innate and adaptive immunity [1]. Unlike traditional alpha-beta T-cell receptors, the TCR gamma delta recognizes antigens, such as non-peptidic phosphoantigens and stress-induced ligands, in a Major Histocompatibility Complex (MHC)-independent manner [2]. This allows these cells to rapidly identify and eliminate infected or transformed cells without the need for classic antigen presentation [4]. In clinical oncology, the receptor is a high-priority target because gamma delta T cells possess natural potent anti-tumor cytotoxicity and have a favorable safety profile regarding graft-versus-host disease [3]. Therapeutic strategies currently include bispecific antibodies that link the TCR gamma delta to specific tumor markers and the development of CAR-gamma delta T cells [5]. Modulation of the receptor's activity, often through butyrophilin-mediated signaling, is actively being explored to treat both hematologic malignancies and solid tumors [1].

Other names

Gamma delta T-cell receptorTCR gamma-deltaTCR γδT-cell receptor γδ complexTCRG/TCRD

Targeting involves the activation of gamma delta T cells via direct agonistic antibodies, bispecific T-cell engagers (TCEs) that bridge the TCR to tumor antigens, or small molecule induction of phosphoantigens to trigger MHC-independent tumor cell lysis and pro-inflammatory cytokine secretion.